{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:10:30Z","timestamp":1793070630785,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,10,30]],"date-time":"2017-10-30T00:00:00Z","timestamp":1509321600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00198-017-4286-7","type":"journal-article","created":{"date-parts":[[2017,10,30]],"date-time":"2017-10-30T02:29:01Z","timestamp":1509330541000},"page":"501-506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur"],"prefix":"10.1007","volume":"29","author":[{"given":"S. L.","family":"Greenspan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Vujevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Britton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Herradura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gruen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Tarkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Siska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Hamlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,30]]},"reference":[{"key":"4286_CR1","unstructured":"Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Suttorp MJ, Motala A, Ewing B, Roth B, Shanman R et al (2012) AHRQ comparative effectiveness reviews. In: Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 Report. edn. Rockville (MD): Agency for Healthcare Research and Quality (US)"},{"issue":"1","key":"4286_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res : Off J Am Soc Bone Miner Res 29(1):1\u201323","journal-title":"J Bone Miner Res : Off J Am Soc Bone Miner Res"},{"issue":"8","key":"4286_CR3","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1001\/jama.2011.190","volume":"305","author":"LY Park-Wyllie","year":"2011","unstructured":"Park-Wyllie LY, Mamdani MM, Juurlink DA, Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ, Laupacis A (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305(8):783\u2013789","journal-title":"JAMA"},{"issue":"18","key":"4286_CR4","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","volume":"364","author":"J Schilcher","year":"2011","unstructured":"Schilcher J, Michaelsson K, Aspenberg P (2011) Bisphoshonate use and atypical fractures of the femoral shaft. N Engl J Med 364(18):1728\u20131737","journal-title":"N Engl J Med"},{"issue":"11","key":"4286_CR5","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1002\/jbmr.253","volume":"25","author":"E Shane","year":"2010","unstructured":"Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res : Off J Am Soc Bone Miner Res 25(11):2267\u20132294","journal-title":"J Bone Miner Res : Off J Am Soc Bone Miner Res"},{"issue":"4","key":"4286_CR6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.11005\/jbm.2015.22.4.183","volume":"22","author":"GI Im","year":"2015","unstructured":"Im GI, Lee SH (2015) Effect of teriparatide on healing of atypical femoral fractures: a systemic review. J Bone Metab 22(4):183\u2013189","journal-title":"J Bone Metab"},{"issue":"1","key":"4286_CR7","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.bone.2012.10.006","volume":"52","author":"CY Chiang","year":"2013","unstructured":"Chiang CY, Zebaze RM, Ghasem-Zadeh A, Iuliano-Burns S, Hardidge A, Seeman E (2013) Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone 52(1):360\u2013365","journal-title":"Bone"},{"issue":"3","key":"4286_CR8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.5371\/hp.2016.28.3.148","volume":"28","author":"JT Kim","year":"2016","unstructured":"Kim JT, Jeong HJ, Lee SJ, Kim HJ, Yoo JJ (2016) Adjuvant teriparatide therapy for surgical treatment of femoral fractures; does it work? Hip Pelvis 28(3):148\u2013156","journal-title":"Hip Pelvis"},{"issue":"2","key":"4286_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.5152\/eurjrheum.2015.0010","volume":"3","author":"SR Mastaglia","year":"2016","unstructured":"Mastaglia SR, Aguilar G, Oliveri B (2016) Teriparatide for the rapid resolution of delayed healing of atypical fractures associated with long-term bisphosphonate use. Eur J Rheumatol 3(2):87\u201390","journal-title":"Eur J Rheumatol"},{"issue":"1","key":"4286_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11914-010-0006-3","volume":"8","author":"SV Bukata","year":"2010","unstructured":"Bukata SV, Puzas JE (2010) Orthopedic uses of teriparatide. Curr Osteoporos Rep 8(1):28\u201333","journal-title":"Curr Osteoporos Rep"},{"issue":"5","key":"4286_CR11","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00774-014-0617-3","volume":"33","author":"N Miyakoshi","year":"2015","unstructured":"Miyakoshi N, Aizawa T, Sasaki S, Ando S, Maekawa S, Aonuma H, Tsuchie H, Sasaki H, Kasukawa Y, Shimada Y (2015) Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide. J Bone Miner Metab 33(5):553\u2013559","journal-title":"J Bone Miner Metab"},{"issue":"4","key":"4286_CR12","first-page":"420","volume":"16","author":"SK Rigler","year":"2002","unstructured":"Rigler SK, Studenski S, Wallace D, Recker D, Duncan PW (2002) Co-morbidity adjustment for functional outcomes in communtiy-dwelling older adults. ClinRehabil 16(4):420\u2013428","journal-title":"ClinRehabil"},{"issue":"6","key":"4286_CR13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473\u2013483","journal-title":"Med Care"},{"key":"4286_CR14","volume-title":"Orthopedic imaging: a practical approach","author":"A Greenspan","year":"2011","unstructured":"Greenspan A (2011) Orthopedic imaging: a practical approach. Lippincott Williams & Wilkins, Philadelphia"},{"key":"4286_CR15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1385\/JCD:2:3:275","volume":"2","author":"LF Varney","year":"1999","unstructured":"Varney LF, Parker RA, Vincelette A, Greenspan SL (1999) Classification of osteoporosis and osteopenia in postmenopausal women is dependent on site-specific analysis. J Clin Densitom 2:275\u2013283","journal-title":"J Clin Densitom"},{"issue":"8","key":"4286_CR16","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1002\/jbmr.2832","volume":"31","author":"SC Kim","year":"2016","unstructured":"Kim SC, Kim DH, Mogun H, Eddings W, Polinski JM, Franklin JM, Solomon DH (2016) Impact of the U.S. Food and Drug Administration\u2019s safety-related announcements on the use of bisphosphonates after hip fracture. J Bone Miner Res : Off J Am Soc Bone Miner Res 31(8):1536\u20131540","journal-title":"J Bone Miner Res : Off J Am Soc Bone Miner Res"},{"issue":"9","key":"4286_CR17","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1002\/jbmr.2202","volume":"29","author":"DH Solomon","year":"2014","unstructured":"Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD (2014) Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res : Off J Am Soc Bone Miner Res 29(9):1929\u20131937","journal-title":"J Bone Miner Res : Off J Am Soc Bone Miner Res"},{"issue":"8","key":"4286_CR18","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/jbmr.2888","volume":"31","author":"S Khosla","year":"2016","unstructured":"Khosla S, Shane E (2016) A crisis in the treatment of osteoporosis. J Bone Miner Res : Off J Am Soc Bone Miner Res 31(8):1485\u20131487","journal-title":"J Bone Miner Res : Off J Am Soc Bone Miner Res"},{"issue":"12","key":"4286_CR19","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1002\/jbmr.2565","volume":"30","author":"S Jha","year":"2015","unstructured":"Jha S, Wang Z, Laucis N, Bhattacharyya T (2015) Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996\u20132012: an ecological analysis. J Bone Miner Res : Off J Am Soc Bone Miner Res 30(12):2179\u20132187","journal-title":"J Bone Miner Res : Off J Am Soc Bone Miner Res"},{"issue":"5","key":"4286_CR20","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1002\/jbmr.3081","volume":"32","author":"NB Watts","year":"2017","unstructured":"Watts NB, Aggers D, McCarthy EF, Savage T, Martinez S, Patterson R, Carrithers E, Miller PD (2017) Responses to treatment with teriparatide in patients with atypical femur fractures previously treated with bisphosphonates. J Bone Miner Res : Off J Am Soc Bone Miner Res 32(5):1027\u20131033","journal-title":"J Bone Miner Res : Off J Am Soc Bone Miner Res"},{"issue":"10","key":"4286_CR21","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1002\/jbmr.1957","volume":"28","author":"M Ellegaard","year":"2013","unstructured":"Ellegaard M, Kringelbach T, Syberg S, Petersen S, Beck Jensen JE, Bruel A, Jorgensen NR, Schwarz P (2013) The effect of PTH(1-34) on fracture healing during different loading conditions. J Bone Miner Res : Off J Am Soc Bone Miner Res 28(10):2145\u20132155","journal-title":"J Bone Miner Res : Off J Am Soc Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-017-4286-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-017-4286-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-017-4286-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T10:18:23Z","timestamp":1551176303000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-017-4286-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,30]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["4286"],"URL":"https:\/\/doi.org\/10.1007\/s00198-017-4286-7","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,30]]},"assertion":[{"value":"27 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Greenspan has received research grants from Eli Lilly and Amgen; Drs. Britton, Herradura, Gruen, Tarkin, Siska, Hamlin, Perera, and K. Vujevich have no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}